Back In The Game: One Year After Rx Exit, P&G Signs On To Promote Silenor
This article was originally published in The Pink Sheet Daily
Somaxon and P&G are preparing to launch the insomnia drug in September with a combined sales force of 215 reps.
You may also be interested in...
Somaxon hopes to launch its insomnia drug in the second half of 2010, but is still searching for a U.S. commercial partner.
In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.
Since many of its key consumer product lines are already mature U.S. brands, Procter & Gamble will have to drive growth by expanding into new markets and acquiring either hard-to-find licenses for OTC switch candidates or existing nonprescription brands.